Low density lipoprotein future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{LDL}} {{CMG}} {{AE}} ==Overview== ==References== {{Reflist|2}} {{Lipoproteins}} Category:Cardiology Category:Lipid disorders Category:Health risks|L..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Investigational Therapies== | |||
===Inhibition of Apolipoprotein B production=== | |||
===PCSK9 Inhibition=== | |||
====Monoclonal Antibodies==== | |||
====Antisense Oligonucleotides==== | |||
====Small Interfering RNAs==== | |||
===Microsomal Triglyceride Transfer Protein Inhibition (MTP)=== | |||
===Thyromimetics=== | |||
===Squalene Synthase Inhibition=== | |||
==References== | ==References== | ||
Revision as of 12:13, 2 October 2013
|
Low Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Low density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Low density lipoprotein future or investigational therapies |
|
FDA on Low density lipoprotein future or investigational therapies |
|
CDC on Low density lipoprotein future or investigational therapies |
|
Low density lipoprotein future or investigational therapies in the news |
|
Blogs on Low density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for Low density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Investigational Therapies
Inhibition of Apolipoprotein B production
PCSK9 Inhibition
Monoclonal Antibodies
Antisense Oligonucleotides
Small Interfering RNAs
Microsomal Triglyceride Transfer Protein Inhibition (MTP)
Thyromimetics
Squalene Synthase Inhibition
References